Rigel Pharma (RIGL) Prices 13M Shares at $7.25
More News related to RIGL
- Morning Movers 11/23: ABIO, SEED, FIF, FNET, DDRX, JOBS Higher; BBI, CGA, BOFL, CEPH Lower
- RBC Upgrades Rigel Pharmaceuticals (RIGL) to Outperform
- Rigel Announces Third Quarter 2009 Financial Results
- Rigel Announces Presentations at Two Investor Conferences
- Rigel to Webcast Analyst Briefing on October 20, 2009
More News related to Equity Offerings
- Wells Fargo Initiates Coverage on American Medical Systems Holdings (AMMD) with an Outperform
- Wells Fargo Initiates Coverage on Varian Medical Systems (VAR) with a Market Perform
- Wells Fargo Initiates Coverage on SAVVIS, Inc. (SVVS) with a Market Perform
- KeyBanc Initiates Coverage on BWAY Holding (BWY) with a Hold; Significant Opportunity, But Near-Term Concerns
- Sidoti & Co Initiates Coverage on Cytec Industries (CYT) with a Neutral
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced the pricing of an underwritten public offering of 13,000,000 shares of its common stock at a price to the public of $7.25 per share. All of the shares are being offered by Rigel. The underwriters have an option to purchase up to an additional 1,950,000 shares to cover over-allotments, if any. The offering is expected to close on September 22, 2009, subject to the satisfaction of customary closing conditions.
Credit Suisse Securities (USA) LLC is acting as the sole book-runner for the offering, with Oppenheimer & Co. Inc. and Thomas Weisel Partners LLC acting as co-managers.
Related Categories
Equity OfferingsStocks Mentioned
-0.05Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
